Dr. Reddy's Plans Semaglutide Launch in Canada as Q4 Profits Drop 86% to ₹2.21B

Market snapshot: Dr. Reddy's Laboratories reported a significant contraction in its Q4 FY26 earnings, with consolidated net profit falling 86% YoY to ₹2.21B. Despite the bottom-line pressure, the company is pivoting towards high-growth complex generics, highlighted by the upcoming launch of generic Semaglutide in India and Canada this month.

Data Snapshot

• Q4 Net Profit: ₹2.21B (vs ₹15.94B YoY)
• Q4 Revenue: ₹75.46B (vs ₹85.3B YoY)
• Q4 EBITDA Margin: 5.07% (vs 23.43% YoY)
• Proposed Dividend: ₹8 per share

What's Changed

• Net Profit fell by 86% YoY, driven primarily by one-time shelf stock adjustments and impairment charges.
• EBITDA margins compressed by 1,836 bps to 5.07%, a multi-year low for the pharmaceutical major.
• Revenue dropped 11.6% YoY as North American sales faced pressure from lower Lenalidomide demand.

Key Takeaways

• One-time charges, including a ₹453 Cr shelf stock adjustment, heavily skewed the Q4 performance.
• Launch of generic Semaglutide in Canada marks the first generic G7 approval, potentially adding $150M in FY27 revenue.
• India and Emerging Markets continue to show resilience with 20-29% growth, offsetting some North American weakness.

SAHI Perspective

While the headline profit drop of 86% appears alarming, it is critical to deconstruct the 'one-offs'. The inclusion of SSA for Lenalidomide and impairment of CAR-T assets totaling over ₹680 Cr explains the bulk of the margin erosion. SAHI views this as a 'clearing of the decks' quarter. The strategic victory lies in the Semaglutide approval—Dr. Reddy's is now positioned to capture the GLP-1 weight-loss and diabetes market ahead of its global peers.

Market Implications

Short-term pressure on the stock is likely as the market digests the margin miss. However, long-term capital allocation signals remain positive given the debt-free balance sheet and steady dividend payout. Sector-wide, this highlights the ongoing pricing volatility in the North American generics market.

Trading Signals

Market Bias: Bearish

Immediate sentiment is Bearish due to the 86% profit collapse and 5.07% margin print, though long-term support exists near the Semaglutide launch catalyst.

Overweight: Complex Generics, GLP-1 Segments

Underweight: North American Generics, Small Molecule Exports

Trigger Factors:

• Actual sales volume of Semaglutide in the Canadian market
• USFDA progress on the Abatacept (interchangeable biosimilar) BLA
• Margin recovery in Q1 FY27 post-one-off adjustments

Time Horizon: Near-term (0-3 months)

Industry Context

The global pharmaceutical industry is shifting toward peptides and biosimilars as 'blockbuster' small molecules face patent cliffs. Dr. Reddy's early entry into the generic Ozempic/Wegovy (Semaglutide) space validates its R&D shift toward complex peptides.

Key Risks to Watch

• Further price erosion in the US generics portfolio.
• Regulatory hurdles or delayed uptake in the Canadian Semaglutide rollout.
• Increased competition as six other players await Canadian approvals.

Recent Developments

On April 29, 2026, Dr. Reddy's received Health Canada approval for its generic Semaglutide injection, becoming the first generic in a G7 nation. In February 2026, the USFDA accepted the BLA for its interchangeable biosimilar, Abatacept. The company also recently integrated a niche consumer healthcare portfolio acquired from Sanofi.

Closing Insight

Investors should look past the Q4 impairment-heavy financials. The structural story remains the company's evolution from a generic player to a complex specialty pharma giant.

FAQs

Why did Dr. Reddy's net profit fall by 86% in Q4?

The decline was primarily due to one-time non-cash items, including a ₹453 Cr shelf stock adjustment (SSA) related to Lenalidomide and over ₹227 Cr in asset impairments.

What is the financial impact of the Canada Semaglutide launch?

Analysts estimate a potential revenue contribution of $150 million (approx. ₹1,250 Cr) in FY27, given Dr. Reddy's first-mover advantage in a market valued at $2 billion.

What does a 5% EBITDA margin mean for retail investors?

While the 5.07% margin is significantly below the historical 23% average, it is largely artificial due to one-time provisions; core operational margins are expected to normalize above 20% in upcoming quarters.

High Performance Trading with SAHI.